Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis Academic Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents
  • Methylprednisolone
  • Multiple Sclerosis, Relapsing-Remitting
  • Prednisone
  • Recovery of Function

abstract

  • SPRINT-MS is designed to evaluate the safety and efficacy of ibudilast as a treatment for PMS while simultaneously validating five different imaging biomarkers as outcome metrics for use in future phase II proof-of-concept PMS trials.

authors

publication date

  • September 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5035622

Digital Object Identifier (DOI)

  • 10.1016/j.cct.2016.08.009

PubMed ID

  • 27521810

Additional Document Info

start page

  • 166

end page

  • 177

volume

  • 50